{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:12:15Z","timestamp":1787501535016,"version":"build-2736575974"},"reference-count":83,"publisher":"Elsevier","isbn-type":[{"value":"9780128126035","type":"print"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/bs.irn.2017.04.012","type":"book-chapter","created":{"date-parts":[[2017,6,10]],"date-time":"2017-06-10T15:15:15Z","timestamp":1497107715000},"page":"1111-1142","source":"Crossref","is-referenced-by-count":8,"title":["Botulinum Toxin Therapy for Nonmotor Aspects of Parkinson's Disease"],"prefix":"10.1016","author":[{"given":"Jaros\u0142aw","family":"S\u0142awek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Madali\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.irn.2017.04.012_bb0005","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1572-0241.2003.07514.x","article-title":"Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A","volume":"98","author":"Albanese","year":"2003","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0010","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/mds.870120524","article-title":"Severe constipation in Parkinson's disease relieved by botulinum toxin","volume":"12","author":"Albanese","year":"1997","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1016\/bs.irn.2017.04.012_bb0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.urology.2013.09.017","article-title":"Onabotulinumtoxin A office treatment for neurogenic bladder incontinence in Parkinson's disease","volume":"83","author":"Anderson","year":"2014","journal-title":"Urology"},{"issue":"3","key":"10.1016\/bs.irn.2017.04.012_bb0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/nau.1930120302","article-title":"Effects of apomorphine and L-dopa on the parkinsonian bladder","volume":"12","author":"Aranda","year":"1993","journal-title":"Neurourology and Urodynamics"},{"issue":"11","key":"10.1016\/bs.irn.2017.04.012_bb0025","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","article-title":"The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease","volume":"24","author":"Barone","year":"2009","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2017.04.012_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pain.2008.12.004","article-title":"Pain in Parkinson's disease: Prevalence and characteristics","volume":"141","author":"Beiske","year":"2009","journal-title":"Pain"},{"key":"10.1016\/bs.irn.2017.04.012_bb0035","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00415-009-5144-0","article-title":"Debilitating consequences of drooling","volume":"256","author":"Bloem","year":"2009","journal-title":"Journal of Neurology"},{"issue":"14","key":"10.1016\/bs.irn.2017.04.012_bb0040","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/mds.21694","article-title":"Botulinum toxin treatment of lateral axial dystonia in parkinsonism","volume":"22","author":"Bonanni","year":"2007","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2017.04.012_bb0045","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3390\/toxins7061882","article-title":"Treatment of gastrointestinal sphincters spasms with botulinum toxin A","volume":"7","author":"Brisinda","year":"2015","journal-title":"Toxins (Basel)"},{"issue":"4","key":"10.1016\/bs.irn.2017.04.012_bb0050","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/mds.24054","article-title":"Prevalence of pain in Parkinson's disease: A systematic review using the modified QUADAS tool","volume":"27","author":"Broen","year":"2012","journal-title":"Movement Disorders"},{"issue":"5","key":"10.1016\/bs.irn.2017.04.012_bb0055","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/cjn.2016.279","article-title":"Botulinum toxin use in refractory pain and other symptoms in parkinsonism","volume":"43","author":"Bruno","year":"2016","journal-title":"The Canadian Journal of Neurological Sciences"},{"issue":"8","key":"10.1016\/bs.irn.2017.04.012_bb0060","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.parkreldis.2014.04.020","article-title":"Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients","volume":"20","author":"Brusa","year":"2014","journal-title":"Parkinsonism & Related Disorders"},{"issue":"18","key":"10.1016\/bs.irn.2017.04.012_bb0065","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1212\/01.wnl.0000260605.12506.86","article-title":"Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease","volume":"68","author":"Brusa","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0070","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1365-2036.2005.02669.x","article-title":"Outlet type constipation in Parkinson's disease: Results of botulinum toxin treatment","volume":"22","author":"Cadeddu","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/bs.irn.2017.04.012_bb0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2012.373","article-title":"Clinical guideline: Management of gastroparesis","volume":"108","author":"Camilleri","year":"2013","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0080","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2017.04.012_bb0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.23929","article-title":"Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: A prospective double-blind trial","volume":"27","author":"Chinnapongse","year":"2012","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2017.04.012_bb0090","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/mds.21646","article-title":"Sialorrhea in Parkinson's disease: A review","volume":"26","author":"Chou","year":"2007","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2017.04.012_bb0095","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/mds.1186","article-title":"Treatment of dystonic clenched fist with botulinum toxin","volume":"16","author":"Cordivari","year":"2001","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2017.04.012_bb0100","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"European Urology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0105","doi-asserted-by":"crossref","first-page":"560","DOI":"10.12968\/ijpn.2010.16.11.80024","article-title":"The management of drooling in motor neuron disease","volume":"16","author":"Dand","year":"2010","journal-title":"International Journal of Palliative Nursing"},{"issue":"6","key":"10.1016\/bs.irn.2017.04.012_bb0110","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1073\/pnas.96.6.3200","article-title":"Functional repair of motor endplates after botulinum neurotoxin type a poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals","volume":"96","author":"de Paiva","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/bs.irn.2017.04.012_bb0115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.parkreldis.2015.03.027","article-title":"Botulinum toxin-a for treatment of Pisa syndrome: A new target muscle","volume":"21","author":"Dupeyron","year":"2015","journal-title":"Parkinsonism & Related Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2017.04.012_bb0120","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/00365590601068835","article-title":"Efficacy and impact of botulinum toxin a on quality of life in patients with neurogenic detrusor overactivity: A randomised, placebo-controlled, double-blind study","volume":"41","author":"Ehren","year":"2007","journal-title":"Scandinavian Journal of Urology and Nephrology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4292\/wjgpt.v7.i3.453","article-title":"Efficacy and safety of botulinum toxin in treatment of anismus: A systematic review","volume":"7","author":"Emile","year":"2016","journal-title":"World Journal of Gastrointestinal Pharmacology and Therapeutics"},{"key":"10.1016\/bs.irn.2017.04.012_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4303\/ne\/235955","article-title":"Evaluating the scope of gastrointestinal symptoms of Parkinson's disease: A review of the evidence","volume":"4","author":"Essa","year":"2016","journal-title":"Neuroenterology"},{"issue":"5","key":"10.1016\/bs.irn.2017.04.012_bb0135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/mds.22260","article-title":"Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation\u2014Critique and recommendations by movement disorders task force on rating scales for Parkinson's disease","volume":"24","author":"Evatt","year":"2009","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2017.04.012_bb0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00384-008-0567-0","article-title":"Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients","volume":"24","author":"Farid","year":"2009","journal-title":"International Journal of Colorectal Disease"},{"key":"10.1016\/bs.irn.2017.04.012_bb0145","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00384-008-0609-7","article-title":"Comparative study between botulinum toxin injection and partial division of puborectalis for treating anismus","volume":"24","author":"Farid","year":"2009","journal-title":"International Journal of Colorectal Disease"},{"issue":"1","key":"10.1016\/bs.irn.2017.04.012_bb0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","article-title":"Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson's disease","volume":"20","author":"Ferreira","year":"2013","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0155","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nrneurol.2009.50","article-title":"Parkinson disease: Pain in Parkinson disease: The hidden epidemic","volume":"5","author":"Ford","year":"2009","journal-title":"Nature Reviews. Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2017.04.012_bb0160","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1353-8020(00)00073-0","article-title":"Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin","volume":"7","author":"Friedman","year":"2001","journal-title":"Parkinsonism & Related Disorders"},{"issue":"3","key":"10.1016\/bs.irn.2017.04.012_bb0165","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.juro.2011.04.071","article-title":"Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder","volume":"186","author":"Giannantoni","year":"2011","journal-title":"The Journal of Urology"},{"issue":"4","key":"10.1016\/bs.irn.2017.04.012_bb0170","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.juro.2009.06.023","article-title":"Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy","volume":"182","author":"Giannantoni","year":"2009","journal-title":"The Journal of Urology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0175","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.parkreldis.2011.01.007","article-title":"Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients","volume":"17","author":"Gil","year":"2011","journal-title":"Parkinsonism & Related Disorders"},{"issue":"6","key":"10.1016\/bs.irn.2017.04.012_bb0180","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"The Journal of Urology"},{"issue":"6","key":"10.1016\/bs.irn.2017.04.012_bb0185","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2340\/16501977-2094","article-title":"Botulinum toxin for foot dystonia in patients with Parkinson's disease having deep brain stimulation: A case series and a pilot study","volume":"48","author":"Gupta","year":"2016","journal-title":"Journal of Rehabilitation Medicine"},{"key":"10.1016\/bs.irn.2017.04.012_bb0190","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.parkreldis.2011.12.004","article-title":"Gastroparesis and Parkinson's disease: A systemic review","volume":"18","author":"Heetun","year":"2012","journal-title":"Parkinsonism & Related Diseases"},{"key":"10.1016\/bs.irn.2017.04.012_bb0195","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1463-1318.2011.02561.x","article-title":"Excellent response rate of anismus to botulinum toxin if rectal prolapse misdiagnosed as anismus (\u2018pseudoanismus\u2019) is excluded","volume":"14","author":"Hompes","year":"2012","journal-title":"Colorectal Disease"},{"key":"10.1016\/bs.irn.2017.04.012_bb0200","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","article-title":"Botulinum toxin in clinical practice","volume":"75","author":"Jankovic","year":"2004","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2017.04.012_bb0205","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.toxicon.2008.11.013","article-title":"Disease-oriented approach to botulinum toxin use","volume":"54","author":"Jankovic","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/bs.irn.2017.04.012_bb0210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14802\/jmd.15008","article-title":"Gastrointestinal autonomic dysfunction in patients with Parkinson's disease","volume":"8","author":"Kim","year":"2015","journal-title":"Journal of Movement Disorders"},{"issue":"8","key":"10.1016\/bs.irn.2017.04.012_bb0215","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.parkreldis.2010.06.006","article-title":"Use of botulinum toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease","volume":"16","author":"Kulaksizoglu","year":"2014","journal-title":"Parkinsonism & Related Disorders"},{"issue":"5","key":"10.1016\/bs.irn.2017.04.012_bb0220","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.20793","article-title":"Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study","volume":"21","author":"Lagalla","year":"2006","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2017.04.012_bb0225","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","article-title":"Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling","volume":"256","author":"Lagalla","year":"2009","journal-title":"Journal of Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2017.04.012_bb0230","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1212\/WNL.61.9.1279","article-title":"A randomized trial of botulinum toxin A for treatment of drooling","volume":"61","author":"Lipp","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2017.04.012_bb0235","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s11255-015-0951-y","article-title":"Underactive and overactive bladders are related to motor function and quality of life in Parkinson's disease","volume":"47","author":"Liu","year":"2015","journal-title":"International Urology and Nephrology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0240","series-title":"New method of botulinum toxin injection for the treatment of spastic pelvic floor syndrome","first-page":"280","author":"Madalinski","year":"2004"},{"key":"10.1016\/bs.irn.2017.04.012_bb0245","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/00042737-200208000-00007","article-title":"Side effects of botulinum toxin injection for benign anal disorders","volume":"14","author":"Madalinski","year":"2002","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0250","first-page":"977","article-title":"Topical nitrates and the higher doses of botulinum toxin for chronic anal fissure","volume":"48","author":"Madalinski","year":"2001","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0255","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.parkreldis.2017.02.024","article-title":"Clinical manifestations of nonmotor symptoms in 1021 Japanese Parkinson's disease patients from 35 medical centers","volume":"38","author":"Maeda","year":"2017","journal-title":"Parkinsonism & Related Disorders"},{"issue":"3","key":"10.1016\/bs.irn.2017.04.012_bb0260","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/nau.21003","article-title":"Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database","volume":"30","author":"Manack","year":"2011","journal-title":"Neurourology and Urodynamics"},{"key":"10.1016\/bs.irn.2017.04.012_bb0265","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/j.1572-0241.2006.00791.x","article-title":"Experience with type A botulinum toxin for treatment of outlet-type constipation","volume":"101","author":"Maria","year":"2006","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0270","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.pain.2010.12.038","article-title":"Deep brain stimulation of the subthalamic nucleus improves temperature sensation in patients with Parkinson's disease","volume":"152","author":"Maruo","year":"2011","journal-title":"Pain"},{"key":"10.1016\/bs.irn.2017.04.012_bb0275","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.3748\/wjg.v21.i22.6842","article-title":"Endoscopic treatment of gastroparesis","volume":"21","author":"McCarty","year":"2015","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0280","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.parkreldis.2016.10.024","article-title":"Lower urinary tract symptoms in Parkinson's disease: Prevalence, etiology and management","volume":"35","author":"McDonald","year":"2017","journal-title":"Parkinsonism & Related Diseases"},{"key":"10.1016\/bs.irn.2017.04.012_bb0285","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11910-014-0511-3","article-title":"An update on the use of botulinum toxin therapy in Parkinson's disease","volume":"15","author":"Mills","year":"2015","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"4","key":"10.1016\/bs.irn.2017.04.012_bb0290","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/WNF.0000000000000037","article-title":"Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of helicobacter pylori infection","volume":"37","author":"Naro\u017ca\u0144ska","year":"2014","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0295","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.parkreldis.2007.07.008","article-title":"Scitigraphic analysis of the parotid glands in patients with sialorrhea and Parkinson's disease","volume":"14","author":"Nicaretta","year":"2008","journal-title":"Parkinsonism & Related Diseases"},{"issue":"2S","key":"10.1016\/bs.irn.2017.04.012_bb0300","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.juro.2016.10.109","article-title":"EMBARK study group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial","volume":"197","author":"Nitti","year":"2017","journal-title":"The Journal of Urology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0305","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.parkreldis.2007.08.003","article-title":"Is drooling secondary to a swallowing disorder in patients with Parkinson's disease?","volume":"14","author":"Nobrega","year":"2008","journal-title":"Parkinsonism & Related Diseases"},{"issue":"1","key":"10.1016\/bs.irn.2017.04.012_bb0310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","article-title":"A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease","volume":"62","author":"Ondo","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0315","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.parkreldis.2014.12.004","article-title":"Prevalence and clinical correlates of drooling in Parkinson disease: A study on 518 Chinese patients","volume":"3","author":"Ou","year":"2015","journal-title":"Parkinsonism & Related Diseases"},{"issue":"3","key":"10.1016\/bs.irn.2017.04.012_bb0320","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mds.870100317","article-title":"\u201cOff\u201d painful dystonia in Parkinson's disease treated with botulinum toxin","volume":"10","author":"Pacchetti","year":"1995","journal-title":"Movement Disorders"},{"issue":"2","key":"10.1016\/bs.irn.2017.04.012_bb0325","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14728214.2012.677949","article-title":"Emerging analgesic drugs for Parkinson's disease","volume":"17","author":"Perez-Lloret","year":"2012","journal-title":"Expert Opinion on Emerging Drugs"},{"key":"10.1016\/bs.irn.2017.04.012_bb0330","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.toxicon.2015.08.014","article-title":"Botulinum toxin A and B in sialorrhea: Long term data and literature overview","volume":"107","author":"Petracca","year":"2015","journal-title":"Toxicon"},{"issue":"4","key":"10.1016\/bs.irn.2017.04.012_bb0335","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp.70.4.538","article-title":"Treatment of sialorrhoea with ultrasound guided botulinum toxin type a injection in patients with neurological disorders","volume":"70","author":"Porta","year":"2001","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2017.04.012_bb0340","series-title":"Botulinum neurotoxin for head and neck disorders","first-page":"213","article-title":"Sialorrhea","author":"Rickert","year":"2012"},{"issue":"5","key":"10.1016\/bs.irn.2017.04.012_bb0350","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/nau.22764","article-title":"Parkinson's disease subcomittee, the neurourology promotion committee in the international continence society. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders","volume":"35","author":"Sakakibara","year":"2016","journal-title":"Neurourology and Urodynamics"},{"issue":"3","key":"10.1016\/bs.irn.2017.04.012_bb0355","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nbd.2011.10.002","article-title":"Pathophysiology of bladder dysfunction in Parkinson's disease","volume":"46","author":"Sakakibara","year":"2012","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2017.04.012_bb0360","series-title":"Manual of botulinum toxin therapy","first-page":"288","article-title":"Botulinum neurotoxin applications in urological disorders","author":"Schurch","year":"2013"},{"issue":"1","key":"10.1016\/bs.irn.2017.04.012_bb0365","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"The Journal of Urology"},{"issue":"Suppl. 3","key":"10.1016\/bs.irn.2017.04.012_bb0370","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","article-title":"The Movement Disorder Society evidence-based medicine review update: Treatments for non-motor symptoms of Parkinson's disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2017.04.012_bb0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000018630","article-title":"Botulin toxin in the treatment of nonrelaxing puborectalis syndrome","volume":"15","author":"Shafik","year":"1998","journal-title":"Digestive Surgery"},{"key":"10.1016\/bs.irn.2017.04.012_bb0380","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.parkreldis.2014.08.013","article-title":"Drooling in Parkinson's disease: A review","volume":"20","author":"Srivanitchapoom","year":"2014","journal-title":"Parkinsonism & Related Diseases"},{"key":"10.1016\/bs.irn.2017.04.012_bb0385","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0030-6665(20)31491-2","article-title":"Salivary gland dysfunction and swallowing disorders","volume":"21","author":"Stuchell","year":"1988","journal-title":"Otolaryngologic Clinics of North America"},{"key":"10.1016\/bs.irn.2017.04.012_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjgast-2016-000118","article-title":"Utility of high-resolution anorectal manometry and wireless motility capsule in the evaluation of patients with Parkinson's disease and chronic constipation","volume":"3","author":"Su","year":"2016","journal-title":"BMJ Open Gastroenterology"},{"key":"10.1016\/bs.irn.2017.04.012_bb0395","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jns.2016.09.061","article-title":"Polyneuropathy in levodopa-treated Parkinson's patients","volume":"371","author":"Szadejko","year":"2016","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/bs.irn.2017.04.012_bb0400","series-title":"Manual of botulinum toxin therapy","first-page":"12","article-title":"Pharmacology of botulinum neurotoxins","author":"Truong","year":"2013"},{"key":"10.1016\/bs.irn.2017.04.012_bb0405","series-title":"Manual of botulinum toxin therapy","first-page":"85","article-title":"Botulinum neurotoxin therapy for laryngeal muscle hyperactivity syndromes","author":"Truong","year":"2013"},{"issue":"12","key":"10.1016\/bs.irn.2017.04.012_bb0410","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/jnnp.2011.241075","article-title":"Urinary dysfunction in early and untreated Parkinson's disease","volume":"82","author":"Uchiyama","year":"2011","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2017.04.012_bb0415","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jnnp.67.5.620","article-title":"Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: A clinicopathological study","volume":"67","author":"Wenning","year":"1999","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2017.04.012_bb0420","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.3748\/wjg.v20.i35.12602","article-title":"Botulinum toxin type-a injection to treat patients with intractable anismus unresponsive to simple biofeedback training","volume":"20","author":"Zhang","year":"2014","journal-title":"World Journal of Gastroenterology"}],"container-title":["International Review of Neurobiology","Nonmotor Parkinson\u2019s: The Hidden Face - Management and the Hidden Face of Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774217300429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774217300429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T19:49:52Z","timestamp":1602272992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774217300429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780128126035"],"references-count":83,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2017.04.012","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}